Association Between Circulating CD4+ T Cell Methylation Signatures of Network-Oriented SOCS3 Gene and Hemodynamics in Patients Suffering Pulmonary Arterial Hypertension.
Benincasa G, Maron BA, Affinito O, D'Alto M, Franzese M, Argiento P, Schiano C, Romeo E, Bontempo P, Golino P, Berrino L, Loscalzo J, Napoli C
This study found that changes in DNA methylation of the SOCS3 gene in immune cells are strongly linked to heart function measures in pulmonary hypertension patients, with lower methylation tied to better heart output and lower pressure in the right heart. SOCS3 levels were also higher in patients' blood, suggesting it may play a role in disease progression and could help predict outcomes.
- SOCS3 gene methylation levels correlate with heart function in PAH patients
- Lower SOCS3 methylation links to better cardiac output and lower right heart pressure
- SOCS3 is overactive in PAH patients' blood cells
- This is the first study linking immune cell methylation to hemodynamics in PAH
- SOCS3 may serve as a blood-based biomarker for PAH severity
Transcriptomic analysis in the striatum reveals the involvement of Nurr1 in the social behavior of prenatally valproic acid-exposed male mice.
Kim H, Woo RS, Yang EJ, Kim HB, Jo EH, Lee S, Im H, Kim S, Kim HS
This study shows that reducing Nurr1 levels in the striatum of mouse models improves social deficits and synaptic health, suggesting a potential therapeutic target for neurodevelopmental conditions. However, the findings are based entirely on animal models and do not provide evidence for human treatments or clinical outcomes.
- Reducing Nurr1 in mouse striatum rescues social deficits and synaptic abnormalities.
- Nurr1 levels are elevated in two different ASD mouse models.
- A known Nurr1 ligand mimics these deficits in healthy mice.
- The study uses prenatal valproic acid exposure to induce ASD-like symptoms in mice.
- No human data, clinical trials, or direct relevance to NR4A2 variants is presented.
Bioinformatics analysis of mRNA profiles and identification of microRNA-mRNA network in CD4+ T cells in seasonal allergic rhinitis.
Jin P, Zhang H, Zhu X, Sun K, Jiang T, Shi L, Zhi L, Zhang H
This study analyzes gene expression in immune cells from patients with seasonal allergies and identifies NR4A2 as one of the few genes consistently altered during allergy seasons. The findings focus on immune system mechanisms like neutrophil activation rather than neurological development or function. This research does not provide information relevant to understanding or treating NR4A2-related neurodevelopmental syndromes.
- NR4A2 appears as a differentially expressed gene in CD4+ T cells during seasonal allergies.
- The study focuses on immune responses, specifically neutrophil activation and degranulation.
- No neurological, developmental, or dopaminergic mechanisms are investigated.
- Results suggest potential targets for allergy treatment, not neurodevelopmental disorders.
The Role of NR4A1 in the Pathophysiology of Osteosarcoma: A Comprehensive Bioinformatics Analysis of the Single-Cell RNA Sequencing Dataset.
Liu W, Hao Y, Tian X, Jiang J, Qiu Q
This study found that NR4A1, not NR4A2, is linked to worse outcomes in osteosarcoma patients, with higher NR4A1 levels tied to shorter survival, metastasis, and resistance to chemotherapy. The analysis used single-cell data to show NR4A1 is more active in certain tumor cells during disease progression.
- NR4A1 levels are higher in metastatic and recurrent osteosarcoma
- High NR4A1 predicts shorter survival in osteosarcoma patients
- NR4A1 is linked to chemotherapy resistance
- NR4A2 expression did not correlate with survival in this study
- NR4A1 may serve as a prognostic marker in osteosarcoma
Identification of Immune Microenvironment Changes and the Expression of Immune-Related Genes in Liver Cirrhosis.
Liu Y, Dong Y, Wu X, Wang X, Niu J
This study analyzes liver tissue from patients with cirrhosis to understand how immune cells change during the disease. It identifies NR4A2 as one of four transcription factors that may regulate natural killer (NK) cell activity in the liver.
- NR4A2 appears in liver tissue data alongside other immune-regulating transcription factors.
- The research focuses on liver cirrhosis, not neurological development or function.
- No clinical data or treatment implications for NR4A2-related syndromes are presented.
NURR1 expression regulates retinal pigment epithelial-mesenchymal transition and age-related macular degeneration phenotypes.
Yao PL, Parmar VM, Choudhary M, Malek G
This study investigates the role of NURR1 in age-related macular degeneration, a common eye disease affecting vision in older adults. It finds that activating NURR1 can protect retinal cells from damage and improve function in mouse models of the disease.
- NURR1 protects retinal pigment epithelial cells from transitioning into scar-like tissue.
- An activator drug improved vision and reduced inflammation in mouse eye models.
- The research focuses on AMD, a distinct condition unrelated to NR4A2-related syndromes.
A Novel Mechanism of Coactivator Recruitment by the Nurr1 Nuclear Receptor.
Daffern N, Radhakrishnan I
This study identifies a specific structural mechanism by which the Nurr1 protein binds to coactivators, revealing how it regulates gene transcription. It shows that a short segment of Nurr1 forms a helix to dock into a groove on the SRC1 protein, a process shared with other transcription factors like STAT6. This work provides fundamental molecular biology insights but does not offer direct clinical guidance or treatment options for NR4A2-related syndromes.
- Nurr1 uses a specific helix segment to bind directly to the SRC1 coactivator protein.
- This binding occurs in a hydrophobic groove shared with other transcription factors like STAT6.
- The research details basic molecular mechanics of gene regulation without clinical application.
- Findings do not translate to immediate therapeutic strategies for NR4A2-related conditions.
Transcriptome landscapes that signify Botrylloides leachi (Ascidiacea) torpor states.
Hyams Y, Panov J, Rosner A, Brodsky L, Rinkevich Y, Rinkevich B
This study analyzes the molecular changes in a marine colonial animal during periods of dormancy, identifying NR4A2 as one of many genes that become more active when the organism is inactive. The research focuses on general survival mechanisms and tissue regeneration in this non-mammalian species rather than human neurological development or disease. It provides no information about NR4A2-related syndromes in children.
- Study examines torpor in a marine colonial animal, not humans or mammals.
- NR4A2 is one of 233 upregulated genes during the dormant state.
- Research focuses on general survival and regeneration mechanisms.
- No clinical data, human genetics, or therapeutic implications are presented.
- Findings do not translate to understanding NR4A2-related neurodevelopmental disorders.
Recruitment of the CoREST transcription repressor complexes by Nerve Growth factor IB-like receptor (Nurr1/NR4A2) mediates silencing of HIV in microglial cells.
Ye F, Alvarez-Carbonell D, Nguyen K, Leskov K, Garcia-Mesa Y, Sreeram S, Valadkhan S, Karn J
This study shows that Nurr1 (NR4A2) directly suppresses HIV transcription in human microglial cells by recruiting repressor complexes to the viral DNA. The findings suggest that activating Nurr1 could potentially silence HIV and reduce neuroinflammation in the brain.
- Nurr1 binds directly to HIV DNA to block viral transcription in human microglia.
- Activating Nurr1 enhances HIV silencing, while reducing it allows viral expression.
- Nurr1 recruits repressor complexes to shut down both HIV and inflammatory genes.
- The research focuses on HIV latency mechanisms, not NR4A2-related syndrome treatments.
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
Willems S, Merk D
This review summarizes current knowledge about small molecules that interact with the Nurr1 protein and discusses their potential role in treating neurodegenerative diseases. It highlights that while structural insights are improving, high-quality chemical tools for controlling Nurr1 are still lacking, meaning target validation is incomplete.
- Nurr1 has neuroprotective and anti-inflammatory properties relevant to neurodegeneration.
- Several small molecule ligands targeting Nurr1 have been identified recently.
- High-quality chemical tools for pharmacological control of Nurr1 are currently insufficient.
- Target validation for Nurr1 as a therapeutic strategy remains pending.
Prolonged cardiac NR4A2 activation causes dilated cardiomyopathy in mice.
Ashraf S, Taegtmeyer H, Harmancey R
Prolonged activation of the NR4A2 gene in heart muscle cells causes severe heart failure and death in mice. This occurs because NR4A2 forces adult heart cells to re-enter the cell cycle without dividing, leading to cell death and structural damage.
- NR4A2 overexpression in mouse hearts leads to dilation, hypertrophy, and fatal heart failure.
- The protein triggers a fetal-like metabolic switch and disassembles heart muscle structures.
- Heart cells attempt to divide but fail, causing multinucleation and subsequent cell death.
- This study focuses exclusively on cardiac tissue, not the nervous system or NR4A2 syndrome.
A Nurr1 ligand C-DIM12 attenuates brain inflammation and improves functional recovery after intracerebral hemorrhage in mice.
Kinoshita K, Yoshimizu A, Ichihara Y, Ushida K, Kotani S, Kurauchi Y, Seki T, Katsuki H
The Nurr1 ligand C-DIM12 reduces brain inflammation and improves functional recovery in mice after intracerebral hemorrhage by suppressing microglial activation and iNOS expression. This preclinical study demonstrates that targeting Nurr1 can protect neurons and preserve axonal transport, suggesting a potential mechanism for neuroprotection.
- C-DIM12 is a Nurr1 ligand that reduces brain inflammation in mice after hemorrhage.
- Treatment improves neurological function and prevents neuron loss in the affected brain area.
- The drug suppresses microglial activation and inflammatory mediators like IL-6.
- Effects involve suppressing iNOS induction, linking Nurr1 signaling to anti-inflammatory outcomes.
- This is a mouse model study with no human clinical data or trials reported.
Regulatory Role of miRNAs and lncRNAs in Gout.
Shu J, Chen M, Ya C, Yang R, Li F
This study identifies a network of non-coding RNAs involved in gout, a condition unrelated to NR4A2-related syndrome. The findings focus on gene regulation in inflammation and immune response, not on neurodevelopmental or neurological disorders. NR4A2 appears in the network but as part of a broader inflammatory pathway, not in the context of its role in brain development or disease.
- NR4A2 is part of a gout-related RNA network
- No link to NR4A2-related neurodevelopmental syndrome
- Findings relate to inflammation, not brain function
- No therapeutic implications for NR4A2 patients
- Study is about gout, not neurogenetic disorders
Effects of bis (2-butoxyethyl) phthalate on adrenocortical function in male rats in puberty partially via down-regulating NR5A1/NR4A1/NR4A2 pathways.
Liu M, Chen H, Dai H, Wang Y, Li J, Tian F, Li Z, Ge RS
Exposure to the chemical BBOP reduces steroid hormone production in male rats by suppressing NR4A2 and related pathways. This study demonstrates that environmental toxins can disrupt adrenal function through mechanisms involving NR4A2, but it does not address neurodevelopmental outcomes or treatments for NR4A2 syndrome.
- BBOP exposure lowers corticosterone and aldosterone levels in pubertal male rats.
- The chemical down-regulates NR4A2 expression alongside other steroidogenesis genes.
- Mechanisms involve reduced AKT/ERK signaling and increased oxidative stress.
- Findings are limited to rat adrenal glands and do not inform human neurodevelopment.
The role of NURR1 in metabolic abnormalities of Parkinson's disease.
Al-Nusaif M, Yang Y, Li S, Cheng C, Le W
This review discusses how the NURR1 protein influences cellular metabolism and contributes to Parkinson's disease pathology. It highlights potential links between metabolic changes and NURR1 function as areas for future therapeutic research.
- NURR1 regulates dopaminergic neuron development and cellular metabolism.
- Metabolic abnormalities are linked to Parkinson's disease progression.
- The paper reviews existing evidence on NURR1's role in disease pathogenesis.
- Potential therapeutic implications of targeting metabolic pathways are discussed.
Lmx1a-Dependent Activation of miR-204/211 Controls the Timing of Nurr1-Mediated Dopaminergic Differentiation.
Pulcrano S, De Gregorio R, De Sanctis C, Lahti L, Perrone-Capano C, Ponti D, di Porzio U, Perlmann T, Caiazzo M, Volpicelli F, Bellenchi GC
This study identifies a molecular switch in developing mouse brains that controls when the Nurr1 protein is produced to help dopamine neurons mature. The research shows that specific microRNAs delay Nurr1 expression until the right developmental stage, ensuring proper neuron formation.
- The mechanism was discovered using mouse brain development models and cell cultures.
- MicroRNAs 204/211 act as a timing switch for the Nurr1 gene.
- This regulation ensures dopamine neurons differentiate at the correct developmental stage.
- No human data or clinical treatments are involved in this research.
Nurr1 Is Not an Essential Regulator of BDNF in Mouse Cortical Neurons.
Abdollahi M, Fahnestock M
This study finds that Nurr1 does not regulate BDNF in mouse cortical neurons, contradicting its known role in other brain regions. The research relies entirely on animal cell models and offers no direct clinical insights for NR4A2-related syndromes.
- Nurr1 fails to control BDNF expression in mouse cortical neurons despite increasing both proteins.
- The study uses only mouse primary cortical neurons and pharmacological agents.
- Results suggest Nurr1's regulatory role is specific to midbrain and cerebellar cells, not the cortex.
- No human data or clinical relevance for NR4A2 patients is presented.
Transcriptome Profiling and Network Analysis Provide Insights Into the Pathogenesis of Vulvar Lichen Sclerosus.
Wang L, Lv Q, Guo J, Wang J, Pan J
This study analyzes vulvar lichen sclerosus, a skin condition unrelated to NR4A2-related syndromes. It finds that NR4A2 is downregulated in affected tissue alongside other immune and cell cycle genes. The research focuses on dermatological pathogenesis rather than neurological development or treatment for NR4A2 disorders.
- Study investigates vulvar lichen sclerosus, a chronic inflammatory skin disease.
- NR4A2 is downregulated in lesions alongside other NR4A family genes.
- Findings relate to T cell activation and reduced cell proliferation in skin.
- No connection to neurodevelopment, dopamine pathways, or pediatric care.
Steroid nuclear receptor coactivator 2 controls immune tolerance by promoting induced Treg differentiation via up-regulating Nr4a2.
Zhang W, Cao X, Zhong X, Wu H, Feng M, Gwack Y, Isakov N, Sun Z
This study identifies a mechanism in the immune system where SRC2 promotes regulatory T cell development by activating the Nr4a2 gene. The findings are based entirely on mouse models and do not provide direct evidence for human treatment or NR4A2-related syndrome management.
- SRC2 activates Nr4a2 to promote regulatory T cell differentiation in mice.
- Mice lacking SRC2 develop autoimmune symptoms and severe inflammation.
- The mechanism involves SRC2 binding to the Nr4a2 promoter via NFAT1.
- This research focuses on immune tolerance, not dopaminergic neuron function.
γ-Glutamylcysteine attenuates amyloid-β oligomers-induced neuroinflammation in microglia via blocking NF-κB signaling pathway.
Bi A, Wang Y, Chen L, Yin Z, Luo L
γ-Glutamylcysteine reduces brain inflammation caused by toxic amyloid-beta proteins by blocking a key inflammatory pathway and boosting protective proteins in brain immune cells. It also lowers oxidative stress and shows protective effects in animal models of Alzheimer's disease.
- γ-Glutamylcysteine reduces brain inflammation from amyloid-beta
- It blocks NF-κB, a major inflammation trigger
- It boosts Nurr1, a protective protein linked to brain health
- It lowers oxidative stress and supports antioxidant defenses
- It shows promise in animal models of neurodegeneration
CREB Inactivation by HDAC1/PP1γ Contributes to Dopaminergic Neurodegeneration in Parkinson's Disease.
Xu X, He X, Zhang Z, Chen Y, Li J, Ma S, Huang Q, Li M
Researchers identify a mechanism in Parkinson's disease where the CREB protein is inactivated, leading to reduced levels of NURR1 and subsequent loss of dopamine-producing neurons. Disrupting this interaction restores NURR1 levels and protects neurons in mouse models.
- CREB inactivation reduces NURR1 expression in Parkinson's patient brains.
- HDAC1/PP1γ complex causes CREB dephosphorylation, impairing neuron survival.
- Blocking this interaction restores NURR1 and protects neurons in mice.
- Study focuses on general Parkinson's pathology, not NR4A2-specific genetics.
Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin.
Januszyk S, Mieszczański P, Lurka H, Sagan D, Boroń D, Grabarek BO
This study found that NR4A2 and several other genes change in response to chemotherapy-induced oxidative stress in endometrial cancer cells, and their activity is likely controlled by specific microRNAs. These changes may help monitor oxidative stress severity, but the findings are in cancer cells, not in people with NR4A2-related syndrome.
- NR4A2 levels change under chemotherapy stress in cancer cells
- NR4A2 is linked to miRNAs that may regulate its activity
- These changes could help track oxidative stress in cancer
- Findings are from cancer cell studies, not human NR4A2 syndrome
- No direct relevance to NR4A2-related neurodevelopmental conditions
Prenatal Hypoxia Affects Nicotine Consumption and Withdrawal in Adult Rats via Impairment of the Glutamate System in the Brain.
Stratilov VA, Vetrovoy OV, Tyulkova EI
Prenatal oxygen deprivation increases nicotine addiction risk in adult rats by altering glutamate signaling in the brain's reward system. This study identifies specific molecular changes in dopamine and glutamate pathways that drive this behavioral shift.
- Prenatal hypoxia predisposes adult rats to higher nicotine consumption.
- Withdrawal symptoms are more severe in prenatally stressed rats.
- Glutamate signaling, not dopamine levels, drives the addiction phenotype.
- Increased glutamate terminals target Nurr1-positive neurons in the VTA.
Nuclear receptor NOR-1 (Neuron-derived Orphan Receptor-1) in pathological vascular remodelling and vascular remodelling.
Ballester-Servera C, Cañes L, Alonso J, Puertas L, Taurón M, Rodríguez C, Martínez-González J
This review describes how NR4A2 and related proteins regulate blood vessel changes in heart and lung diseases. It does not provide information on NR4A2-related syndrome or treatments for children.
- NR4A2 helps control cell survival and inflammation in blood vessels.
- The paper focuses on atherosclerosis, aneurysms, and pulmonary hypertension.
- It is a review of vascular biology mechanisms.
- No clinical data or pediatric relevance is presented.
Yeast beta-glucan mediates histone deacetylase 5-induced angiogenesis in vascular endothelial cells.
Choi M, Lee SM, Lee JW, Kim I, Pack CG, Ha CH
Yeast beta-glucan promotes blood vessel formation by activating HDAC5, which turns on genes involved in angiogenesis, including NR4A2. Blocking HDAC5 stops this process, showing that beta-glucan works through this specific pathway.
- Beta-glucan triggers blood vessel growth via HDAC5 activation
- HDAC5 moves to the cell's cytoplasm when stimulated by beta-glucan
- NR4A2 is turned on as part of this pro-angiogenic process
- Blocking HDAC5 stops beta-glucan’s effect on blood vessel formation
- Beta-glucan may be a potential therapy for conditions needing new blood vessels
Wnt/β-catenin signaling pathway is involved in early dopaminergic differentiation of trabecular meshwork-derived mesenchymal stem cells.
Sahebdel F, Parvaneh Tafreshi A, Arefian E, Roussa E, Nadri S, Zeynali B
This study shows that stem cells from the eye's trabecular meshwork convert into dopamine-producing neurons more effectively than bone marrow or fat stem cells when stimulated by specific signaling pathways. The researchers identify the Wnt/beta-catenin pathway as a key driver for this transformation, suggesting it could be a target for future cell-based therapies.
- Trabecular meshwork stem cells show higher neural potential than bone marrow or fat stem cells.
- Wnt/beta-catenin activation directs these stem cells toward a dopamine-producing fate.
- The study uses only cell cultures, with no animal or human testing involved.
- Nurr-1 expression confirms early differentiation into dopaminergic neurons in the lab setting.
Construction of lncRNA-miRNA-mRNA network based on ceRNA mechanism reveals the function of lncRNA in the pathogenesis of gout.
Chen F, Zhang X, Chen Y, Chai Y, Jiang X, Li H
This study found that a network of lncRNAs, miRNAs, and mRNAs helps drive gout by disrupting key inflammatory pathways, including NF-κB and IL-17 signaling, with NR4A2 identified as a central hub gene involved in this process.
- NR4A2 is a key hub gene in the ceRNA network of gout
- The lncRNA-miRNA-mRNA network affects inflammation and joint cell function
- Five lncRNAs and five miRNAs are linked to gout development
- The network influences NF-κB, IL-17, and TNF signaling pathways
- Findings may point to new treatment targets for gout
Prostaglandin A2 Interacts with Nurr1 and Ameliorates Behavioral Deficits in Parkinson's Disease Fly Model.
Rajan S, Toh HT, Ye H, Wang Z, Basil AH, Parnaik T, Yoo JY, Lim KL, Yoon HS
Prostaglandin A2 binds directly to the Nurr1 protein and rescues movement deficits in a fruit fly model of Parkinson's disease. This study provides structural evidence that PGA2 activates Nurr1, suggesting it could potentially modulate the pathway affected by NR4A2 mutations.
- PGA2 physically binds to the Nurr1 ligand-binding domain via covalent coupling.
- Binding shifts the AF-2 helix, activating Nurr1 transcriptional function.
- PGA2 rescues locomotor deficits in LRRK2 mutant fruit flies.
- Study uses insect models, not human patients or mammalian systems.
Orphan Nuclear Receptor NR4A2 Is Constitutively Expressed in Cartilage and Upregulated in Inflamed Synovium From hTNF-Alpha Transgenic Mice.
Lilley CM, Alarcon A, Ngo MH, Araujo JS, Marrero L, Mix KS
This study shows that NR4A2 levels rise in joint tissue during inflammation in a mouse model of rheumatoid arthritis. It confirms that NR4A2 is part of the inflammatory process in joints but does not address its role in dopaminergic neurons or movement disorders.
- NR4A2 increases in inflamed synovium of mice with rheumatoid arthritis.
- The study focuses on joint inflammation, not brain or dopamine pathways.
- Results validate the mouse model for testing drugs targeting NR4A2 in arthritis.
- No findings apply to NR4A2-related syndromes affecting movement or development.
Disrupted myelination network in the cingulate cortex of Parkinson's disease.
Xie S, Yang J, Huang S, Fan Y, Xu T, He J, Guo J, Ji X, Wang Z, Li P, Chen J, Zhang Y
This study identifies disrupted myelination in the cingulate cortex of Parkinson's disease patients and highlights NR4A2 as one of several genes implicated in this neurodegenerative process. The findings suggest that remyelination strategies could be a potential therapeutic approach for cognitive symptoms in Parkinson's.
- Myelin genes are downregulated in the cingulate cortex of Parkinson's patients.
- Oligodendrocytes, which produce myelin, are the primary damaged cell type.
- NR4A2 is listed among seven genes implicated in PD or neurodegeneration.
- Results validate findings from a separate dementia with Lewy Bodies cohort.
- Remyelination is proposed as a promising treatment strategy for Parkinson's.
Essential Roles of the Transcription Factor NR4A1 in Regulatory T Cell Differentiation under the Influence of Immunosuppressants.
Sekiya T, Kasahara H, Takemura R, Fujita S, Kato J, Doki N, Katayama Y, Ozawa Y, Takada S, Eto T, Fukuda T, Ichinohe T, Takanashi M, Onizuka M, Atsuta Y, Okamoto S, Yoshimura A, Takaki S, Mori T
This study investigates NR4A1, a different gene from the NR4A2 gene affecting your child, focusing on immune system regulation rather than neurological development. The research demonstrates how NR4A1 influences regulatory T cells in the context of immunosuppressant therapy and transplant outcomes.
- The paper studies NR4A1, not NR4A2, which is the gene relevant to your child's condition.
- Research focuses on immune cell differentiation and transplant medicine, not brain development.
- Findings involve mouse models and human transplant patients regarding graft-versus-host disease.
- No direct implications for NR4A2-related neurodevelopmental disorders or treatments are presented.
Identification and Verification of Potential Hub Genes in Amphetamine-Type Stimulant (ATS) and Opioid Dependence by Bioinformatic Analysis.
Zhang W, Deng X, Liu H, Ke J, Xiang M, Ma Y, Zhang L, Yang M, Liu Y, Huang F
This bioinformatic study identifies Nr4a2 as a hub gene involved in neuron differentiation and proliferation within mouse models of drug dependence. The research confirms that Nr4a2 expression changes in response to amphetamine and opioid treatments, linking it to the PI3K/Akt signaling pathway.
- Nr4a2 appears as a key hub gene in mouse models of amphetamine and opioid dependence.
- The study links Nr4a2 to neuron differentiation, migration, and proliferation processes.
- Nr4a2 expression changes were observed in both bioinformatic data and cell line validation.
- The PI3K/Akt signaling pathway is implicated in the pathogenesis of substance dependence.
Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease.
Kim J, Park I, Jang S, Choi M, Kim D, Sun W, Choe Y, Choi JW, Moon C, Park SH, Choe HK, Kim K
This preclinical study in mice shows that a drug targeting the REV-ERBα protein reduces anxiety and depression-like behaviors linked to circadian rhythms. The treatment also restores normal function of NURR1, a protein related to NR4A2, within dopamine-producing neurons.
- The study uses Parkinson's disease mouse models, not humans or NR4A2 patients.
- SR8278 reduces mood disorders and restores circadian rhythms in mice.
- The drug normalizes NURR1 binding to DNA in dopamine neurons.
- Findings suggest REV-ERBα antagonism may help with non-motor symptoms in Parkinson's.
ADRAM is an experience-dependent long noncoding RNA that drives fear extinction through a direct interaction with the chaperone protein 14-3-3.
Wei W, Zhao Q, Wang Z, Liau WS, Basic D, Ren H, Marshall PR, Zajaczkowski EL, Leighton LJ, Madugalle SU, Musgrove M, Periyakaruppiah A, Shi J, Zhang J, Mattick JS, Mercer TR, Spitale RC, Li X, Bredy TW
This study identifies a specific RNA molecule in mice that helps form fear extinction memories by interacting with the NR4A2 gene. The findings describe a molecular mechanism in mouse models and do not provide clinical evidence or treatment options for humans.
- Researchers studied fear extinction memory mechanisms in adult male mice.
- An RNA called ADRAM recruits the 14-3-3 protein to the Nr4a2 gene promoter.
- This interaction is required for forming fear extinction memories in mice.
- The study focuses on basic molecular biology without human clinical data.
Identification of differentially expressed genes and signaling pathways with Candida infection by bioinformatics analysis.
Zhu GD, Xie LM, Su JW, Cao XJ, Yin X, Li YP, Gao YM, Guo XG
This study used computational analysis to identify genes and pathways activated during Candida infections, finding that JUNB, ATF3, and EGR2 are consistently altered across different Candida species and may serve as potential biomarkers for infection.
- JUNB, ATF3, and EGR2 are consistently changed in Candida infections
- These genes may help detect Candida infections early
- The findings come from analyzing human infection data
- Results suggest possible new ways to diagnose Candida infections
Autistic-like behavior and cerebellar dysfunction in Bmal1 mutant mice ameliorated by mTORC1 inhibition.
Liu D, Nanclares C, Simbriger K, Fang K, Lorsung E, Le N, Amorim IS, Chalkiadaki K, Pathak SS, Li J, Gewirtz JC, Jin VX, Kofuji P, Araque A, Orr HT, Gkogkas CG, Cao R
Disrupting the Bmal1 gene in mice causes autism-like behaviors and problems in the cerebellum, including abnormal brain cell connections and impaired neuron function. These issues are linked to overactive mTORC1 signaling, which can be reversed by the drug metformin, improving both behavior and brain cell health.
- Bmal1 gene loss causes autism-like behaviors in mice
- Cerebellum cells show abnormal structure and function
- mTORC1 signaling is overactive and linked to symptoms
- Metformin reduces mTORC1 and improves symptoms
- Cerebellum-specific Bmal1 loss is enough to cause issues
The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes.
Martire S, Valentino P, Marnetto F, Mirabile L, Capobianco M, Bertolotto A
Storing blood in EDTA tubes before processing affects gene expression, especially for inflammation-related genes like NR4A2, even after just 2 hours at room temperature or 4°C. This means delays in handling blood samples can lead to inaccurate results in gene studies.
- Delays in processing blood affect NR4A2 and other inflammation genes
- Even 2 hours at 4°C or room temperature alters gene expression
- B2M is the most stable reference gene for normalization
- Standardized handling is critical for reliable results
- RNA quality remains stable, but expression levels change
Structural, molecular hybridization and network based identification of miR-373-3p and miR-520e-3p as regulators of NR4A2 human gene involved in neurodegeneration.
Singh J, Raina A, Sangwan N, Chauhan A, Avti PK
Computational modeling identifies miR-373-3p and miR-520e-3p as strong candidates for regulating the NR4A2 gene by binding to its mRNA. This study provides theoretical evidence of potential molecular interactions but does not test these findings in biological systems or humans.
- The study uses computer simulations, not wet-lab experiments or human data.
- It predicts miR-373-3p and miR-520e-3p bind tightly to NR4A2 mRNA.
- No experimental validation confirms these interactions occur in living cells.
- The research focuses on theoretical network analysis of gene regulation.
Ferulic Acid Induces NURR1 Expression and Promotes Dopaminergic Differentiation in Neural Precursor Cells.
Sadeghi-Zadeh M, Homayouni Moghadam F, Nasr-Esfahani MH
Ferulic acid increases NURR1 expression and promotes the differentiation of neural precursor cells into dopaminergic neurons in mouse stem cell cultures. This study demonstrates a molecular mechanism by which ferulic acid supports dopaminergic development, but it does not provide evidence of clinical efficacy or safety in humans.
- Ferulic acid boosts NURR1 and TH gene expression in mouse neural stem cells.
- Treatment enhances neurite length and overall dopaminergic differentiation rates.
- The study uses only mouse cell cultures, with no human or animal data.
- No clinical trials or patient outcomes are reported for this intervention.